Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China.

Li J, Li X, Chen YP, Chen ZM, Zhang LH, Feng F, Zhang HB, Liu JM, Gao Y, Hundei WB, Li L, Jiang LX.

Chin Med J (Engl). 2013;126(18):3451-5.

PMID:
24034088
2.

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.

Sharma KK, Gupta R, Agrawal A, Roy S, Kasliwal A, Bana A, Tongia RK, Deedwania PC.

Vasc Health Risk Manag. 2009;5:1007-14. Epub 2009 Nov 23.

3.

Influence of education and working background on physicians' knowledge of secondary prevention guidelines for coronary heart disease: results from a survey in China.

Gong YJ, Hong T, Jiang J, Yu RH, Zhang Y, Liu ZP, Huo Y.

J Zhejiang Univ Sci B. 2012 Mar;13(3):231-8. doi: 10.1631/jzus.B1100299.

4.

The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.

Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O.

J Clin Pharm Ther. 2013 Apr;38(2):97-100. doi: 10.1111/jcpt.12027. Epub 2013 Feb 26.

PMID:
23441979
5.

Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).

Zeymer U, Berkenboom G, Coufal Z, Belger M, Sartral M, Norrbacka K, Bakhai A; APTOR investigators..

Int J Cardiol. 2013 Dec 10;170(2):239-45. doi: 10.1016/j.ijcard.2013.10.057. Epub 2013 Oct 26.

PMID:
24225199
6.

Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.

Pereira M, Araújo C, Dias P, Lunet N, Subirana I, Marrugat J, Capewell S, Bennett K, Azevedo A.

Eur J Prev Cardiol. 2014 Nov;21(11):1401-8. doi: 10.1177/2047487313494580. Epub 2013 Jun 20.

PMID:
23787795
7.

Trends in pharmacological therapy following an acute coronary syndrome in Portugal: a systematic review.

Pereira M, Lopes-Conceição L, Bennett K, Dias P, Laszczynska O, Lunet N, Azevedo A.

J Cardiovasc Med (Hagerstown). 2016 Sep;17(9):639-46. doi: 10.2459/JCM.0000000000000258. Review.

PMID:
26263047
8.

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators..

Lancet. 2011 Oct 1;378(9798):1231-43. doi: 10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26.

PMID:
21872920
9.

Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.

Kassab YW, Hassan Y, Aziz NA, Akram H, Ismail O.

J Eval Clin Pract. 2013 Aug;19(4):658-63. doi: 10.1111/j.1365-2753.2012.01894.x. Epub 2012 Jul 29.

PMID:
22845427
10.
11.

[Analysis of current treatment practice and outcomes for in-patients with ST-segment elevation acute coronary syndrome in 31 provinces of China].

Bridging the Gap on Coronary Heart Disease Secondary Prevention in China..

Beijing Da Xue Xue Bao. 2011 Jun 18;43(3):440-5. Chinese.

12.

Evidence-based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non-Aboriginal patients admitted to Western Australian hospitals.

Gausia K, Katzenellenbogen JM, Sanfilippo FM, Knuiman MW, Thompson PL, Hobbs MS, Thompson SC.

Intern Med J. 2014 Apr;44(4):353-61. doi: 10.1111/imj.12375.

PMID:
24528930
13.

Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.

Li J, Chen YP, Li X, Armitage J, Feng F, Liu JM, Gao Y, Zhang HB, Zhang D, Hundei WB, Chen ZM, Chen F, Hopewell JC, Valdes-Marquez E, Landray M, Jiang LX; HPS2-THRIVE Collaborative Group..

Chin Med J (Engl). 2012 Dec;125(24):4361-7.

PMID:
23253702
14.

Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge.

Jin H, Tang C, Wei Q, Chen L, Sun Q, Ma G, Liu N.

BMC Cardiovasc Disord. 2014 Sep 24;14:127. doi: 10.1186/1471-2261-14-127.

15.

Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians' survey in China.

Jiang J, Hong T, Yu R, Zhang Y, Liu Z, Huo Y; 11th 5-Year National Key Technologies R&D Program for CHD-Coronary Heart Disease Secondary Prevention Research Group..

Eur J Prev Cardiol. 2012 Oct;19(5):991-8. doi: 10.1177/1741826711421299. Epub 2011 Aug 22.

PMID:
21859776
16.

Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.

Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, Moore N, Droz-Perroteau C, Fourrier-Reglat A.

Eur J Clin Pharmacol. 2014 Apr;70(4):429-36. doi: 10.1007/s00228-013-1614-5. Epub 2013 Nov 24.

PMID:
24271648
17.
18.

[Current clinical practice patterns and outcome for acute coronary syndromes in China: results of BRIG project.].

Liu Q, Zhao D, Liu J, Wang W, Liu J; Bridging the Gap on Coronary Heart Disease Secondary Prevention in China..

Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Mar;37(3):213-7. Chinese.

PMID:
19781143
19.

Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Turnbull F; CPACS Investigators..

Am Heart J. 2009 Mar;157(3):509-516.e1. doi: 10.1016/j.ahj.2008.09.026. Epub 2008 Dec 17.

PMID:
19249422
20.

[Real world use of statins for secondary prevention in patients with high risk coronary heart disease in China].

Li HJ, Liu J, Liu J, Wang W, Qin LP, Li Y, Wang M, Sun JY, Qi Y, Zhao D.

Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Nov;38(11):1033-7. Chinese.

PMID:
21215234

Supplemental Content

Support Center